Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure ...United Arab Emirates

Economy by : (CNBC) -
Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure )

Also on site :

Most Viewed Economy
جديد الاخبار